In a recent filing, Ian Blackman has amended his convertible promissory notes and warrants associated with NexGel, Inc. This significant adjustment, reported on November 13, 2026, indicates a strategic shift as the company prepares for a potential merger.

NexGel, Inc., identified under the SIC code for surgical and medical instruments and apparatus, is based in Langhorne, Pennsylvania. The company has been active in the market, with recent filings indicating ongoing developments in its financial structure.

The filing states that on November 10, 2026, Blackman entered into a Note Amendment and Conversion Agreement with NexGel. This agreement notably reduced the conversion price of his Convertible Promissory Note from $12.00 to $5.50 per share and adjusted the exercise price of his Existing Warrant from $16.00 to $13.00 per share. The filing emphasizes that these amendments are treated as a disposition of the original derivatives, which remain outstanding in their amended form.

These changes could significantly impact Blackman's ownership stake and the overall capital structure of NexGel. The adjustments were approved by the company’s Board of Directors and are part of a broader strategy as the company approaches a contemplated merger.

Details were not available in the SEC filing regarding what specific outcomes may result from these amendments or the anticipated timeline for the merger. However, the nature of these changes suggests a proactive approach to enhance the company's financial positioning in a competitive market.